Thrombogenics

Last updated: 13.02.2014

Address: Gaston Geenslaan 1
B-3001 Heverlee
Belgium

Tel: +32 (0) 16 75 13 10

Web: http://thrombogenics.com/

Company description

Thrombogenics NV is a Belgium-based biopharmaceutical company focused on the discovery and development of medicines for the treatment of eye disease, vascular disease and cancer. The Company’s lead drug candidateocriplasmin (microplasmin), completed two phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). The TN-402 (Anti-factor VIII) drug candidate against deep vein thrombosis and atrial fibrillation is in phase I of the clinical trials. The TB-403 anticancer agent was licensed to F. Hoffmann La Roche AG which will subject it to phase II clinical trials. The Staphylokinase candidate against Acute myocardial infarction (AMI) successfully completed phase II clinical trials. The Company has its Branch in Ireland and also subsidiary in the United States.

Products and services

The Company’s lead drug candidateocriplasmin (microplasmin), completed two phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). The TN-402 (Anti-factor VIII) drug candidate against deep vein thrombosis and atrial fibrillation is in phase I of the clinical trials. The TB-403 anticancer agent was licensed to F. Hoffmann La Roche AG which will subject it to phase II clinical trials. The Staphylokinase candidate against Acute myocardial infarction (AMI) successfully completed phase II clinical trials. The Company has its Branch in Ireland and also subsidiary in the United States.

Interviews

Related

We use cookies to ensure that we give you the best experience on our site. For more info click here